Our group studies malaria, with an emphasis on disease pathogenesis, host-parasite interactions, and clinical research in affected populations. Our long-range goal is to develop the next generation of malaria vaccines. P. falciparum is the most deadly of the malaria parasites infecting humans. We are applying advanced technologies, including DNA and protein microarrays, and proteomic studies, to study the parasite and identify the most promising antigens for inclusion in future vaccines. We have established laboratories in Muheza and Morogoro, Tanzania, to conduct research on pregnant mothers and young children, who suffer the greatest burden of malarial illness. At Seattle Biomedical Research Institute, we launched the Malaria Program in 2001 with the generous support of the Bill and Melinda Gates Foundation. This program has expanded to involve six laboratories, and encompasses a range of activities, including vaccines against pregnancy malaria and severe malaria of children, attenuated malaria vaccines against the liver stage parasite, and studies of new drugs and diagnostics for pregnant women, among many other projects led by different scientists in the program.